Hang Tran

1.0k total citations
18 papers, 569 citations indexed

About

Hang Tran is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hang Tran has authored 18 papers receiving a total of 569 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hang Tran's work include Cancer Genomics and Diagnostics (4 papers), Renal cell carcinoma treatment (3 papers) and Epigenetics and DNA Methylation (2 papers). Hang Tran is often cited by papers focused on Cancer Genomics and Diagnostics (4 papers), Renal cell carcinoma treatment (3 papers) and Epigenetics and DNA Methylation (2 papers). Hang Tran collaborates with scholars based in United States, Vietnam and Italy. Hang Tran's co-authors include Beth Y. Karlan, Rae Lynn Baldwin, Ilana Cass, Elizabeta Nemeth, Steven A. Narod, Hyun S. Shvartsman, Daniel R. Scoles, Barbie Taylor‐Harding, Xuan Xu and James Pavelka and has published in prestigious journals such as Journal of Clinical Oncology, Emerging infectious diseases and Carcinogenesis.

In The Last Decade

Hang Tran

17 papers receiving 561 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hang Tran United States 9 402 215 139 128 126 18 569
Yinhua Yu China 8 284 0.7× 176 0.8× 108 0.8× 84 0.7× 68 0.5× 10 465
Philip C. Schouten Netherlands 12 325 0.8× 326 1.5× 243 1.7× 94 0.7× 169 1.3× 26 649
Robert L. Hollis United Kingdom 15 255 0.6× 256 1.2× 138 1.0× 431 3.4× 98 0.8× 32 695
Tabari M. Baker United States 6 234 0.6× 265 1.2× 98 0.7× 40 0.3× 63 0.5× 12 406
Adriaan Vanderstichele Belgium 14 288 0.7× 300 1.4× 327 2.4× 266 2.1× 87 0.7× 29 752
Jay Pilrose United States 8 422 1.0× 128 0.6× 229 1.6× 87 0.7× 34 0.3× 12 567
Betül T. Yesilyurt Belgium 8 184 0.5× 194 0.9× 140 1.0× 79 0.6× 38 0.3× 9 452
Bożena Konopka Poland 13 319 0.8× 84 0.4× 154 1.1× 129 1.0× 51 0.4× 23 468
Wa Zhang United States 13 454 1.1× 192 0.9× 130 0.9× 80 0.6× 69 0.5× 15 668
Terry Hurst Australia 11 276 0.7× 157 0.7× 63 0.5× 202 1.6× 57 0.5× 18 477

Countries citing papers authored by Hang Tran

Since Specialization
Citations

This map shows the geographic impact of Hang Tran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hang Tran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hang Tran more than expected).

Fields of papers citing papers by Hang Tran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hang Tran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hang Tran. The network helps show where Hang Tran may publish in the future.

Co-authorship network of co-authors of Hang Tran

This figure shows the co-authorship network connecting the top 25 collaborators of Hang Tran. A scholar is included among the top collaborators of Hang Tran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hang Tran. Hang Tran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Jiang, Zhe, Philip E.D. Chung, Hang Tran, et al.. (2025). Recent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities. Cancers. 17(5). 720–720. 1 indexed citations
2.
Tran, Hang, et al.. (2023). Epidemiologic Characteristics of Mpox Infections among People Experiencing Homelessness, Los Angeles County, California, USA, 2022. Emerging infectious diseases. 29(6). 1109–1116. 4 indexed citations
3.
4.
5.
6.
Cheon, Dong‐Joo, Andrew J. Li, Jessica A. Beach, et al.. (2015). ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma. Carcinogenesis. 36(7). 739–747. 21 indexed citations
7.
Tran, Hang, Amelia Rodríguez Martín, Amado J. Zurita, et al.. (2011). Plasma cytokine and angiogenic factors (CAFs) predictive of clinical benefit and prognosis in patients (Pts) with advanced or metastatic renal cell cancer (mRCC) treated in phase III trials of pazopanib (PAZO).. Journal of Clinical Oncology. 29(7_suppl). 334–334. 8 indexed citations
8.
Papadimitrakopoulou, V., John V. Heymach, Stephen Jay Frank, et al.. (2011). Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 29(15_suppl). 5510–5510. 4 indexed citations
9.
Lieu, Christopher H., Hang Tran, Michael J. Overman, et al.. (2011). The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.. Journal of Clinical Oncology. 29(15_suppl). 3533–3533. 18 indexed citations
10.
Tran, Hang, Yen‐Ting Lin, Katherine L. Baker-Neblett, et al.. (2010). Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients.. Journal of Clinical Oncology. 28(15_suppl). 4522–4522. 6 indexed citations
11.
Scoles, Daniel R., et al.. (2009). Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein. Gynecologic Oncology. 116(1). 109–116. 56 indexed citations
12.
Tannir, Nizar M., Amado J. Zurita, John V. Heymach, et al.. (2008). A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. Journal of Clinical Oncology. 26(15_suppl). 5093–5093. 10 indexed citations
13.
14.
Walsh, Christine, Seishi Ogawa, Hisae Karahashi, et al.. (2008). ERCC5 Is a Novel Biomarker of Ovarian Cancer Prognosis. Journal of Clinical Oncology. 26(18). 2952–2958. 63 indexed citations
15.
Scoles, Daniel R., James Pavelka, Ilana Cass, et al.. (2006). Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. Gynecologic Oncology. 104(1). 120–128. 11 indexed citations
16.
Baldwin, Rae Lynn, Hang Tran, & Beth Y. Karlan. (2003). Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.. PubMed. 63(6). 1413–9. 50 indexed citations
17.
Baldwin, Rae Lynn, Elizabeta Nemeth, Hang Tran, et al.. (2000). BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.. PubMed. 60(19). 5329–33. 268 indexed citations
18.
Baldwin, Rae Lynn, Hang Tran, & Beth Y. Karlan. (1999). Primary Ovarian Cancer Cultures are Resistant to Fas-Mediated Apoptosis. Gynecologic Oncology. 74(2). 265–271. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yinhua Yu Breakdown of academic impact, for papers by Philip C. Schouten Breakdown of academic impact, for papers by Robert L. Hollis Breakdown of academic impact, for papers by Tabari M. Baker Breakdown of academic impact, for papers by Adriaan Vanderstichele Breakdown of academic impact, for papers by Jay Pilrose Breakdown of academic impact, for papers by Betül T. Yesilyurt Breakdown of academic impact, for papers by Bożena Konopka Breakdown of academic impact, for papers by Wa Zhang Breakdown of academic impact, for papers by Terry Hurst
Rankless by CCL
2026